A new industry analysis highlights the core commercialization challenge for CAR-T: scaling thousands of patient-specific manufacturing runs so they behave like one reliable system. The piece frames the “scale-out” problem as an operations and process-control issue, where variability across manufacturing lots can complicate throughput, timing, and outcomes. The analysis points to in vivo production as one potential path—an approach meant to shift manufacturing from centralized ex vivo facilities toward patient-local or body-based generation. Even with such strategies, the underlying problem remains standardizing production performance across patients and sites. For the CAR-T market, the message is direct—manufacturing automation and process harmonization are becoming as decisive as clinical safety and efficacy for long-term adoption.